Toxicity, Drug
12
3
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
TIL and Anti-PD1 in Metastatic Melanoma
Observation Study of the Pharmacokinetics of Adductor Canal Block
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials
Apatinib for Inoperable Advanced Chondrosarcoma
Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma